Commentary: FDA too cautious

05/17/2007 | Wall Street Journal, The

The FDA acted outside its authority when it rejected Arcoxia because the company had not proven the drug was superior to one already on the market, a Hoover Institute fellow and an industry consultant write in this Wall Street Journal commentary. The authors say such a stance is too cautious and limits treatment options.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Senior Counsel – Regulatory Affairs
RAI Services Company
Winston-Salem, NC